- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02008435
Increasing the Effectiveness of the Diabetes Prevention Program
20 mars 2018 mis à jour par: Barbel Knauper, McGill University
Increasing the Effectiveness of the Diabetes Prevention Program Through If-then Plans and Mental Practice: A Parallel Randomized Trial
The Diabetes Prevention Program (DPP) is highly effective in promoting weight loss in overweight and obese individuals (e.g., 7% average loss of body weight), and thereby reducing the risk of developing weight-related health consequences.
One-on-one DPP sessions, however, are costly and the group-delivered DPP version, the Group Lifestyle Balance program (GLB), is less effective (4% average loss of body weight).
The aim of this two-arm parallel randomized controlled trial is to increase the effectiveness of the GLB by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
The study will provide evidence-based data on the effectiveness of an enhanced GLB intervention in promoting weight loss and in reducing weight-related risk factors for chronic health problems.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
Please see brief summary.
Type d'étude
Interventionnel
Inscription (Réel)
172
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1B1
- McGill University
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 75 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- men and women
- ages of 18 and 75
- overweight or obese (BMI 28-45 kg/m2)
- sedentary (< 200 min/week of moderate or vigorous exercise)
- waist circumference of >= 88cm for women and >= 102cm for men
Exclusion Criteria:
- diabetes (hemoglobin A1c < 7.0%).
- taking the medication metformin (used for treating pre-diabetes or diabetes)
- having been pregnant in the past 6 months or planning on becoming pregnant in the next 2 years
- currently undergoing treatment for cancer
- using medication that affects body weight (e.g., loop diuretics)
- being unable to participate in regular moderate physical activity
- having severe uncontrolled hypertension (> 190/100mm Hg)
- being unable to communicate in English or French
- being diagnosed with bulimia nervosa, currently active major depression, or other severe psychiatric disease (including dementia);
- suffering from a heart attack, stroke, or heart failure within the past 6 months
- experiencing excessive weight loss (more than 10 pounds or 4.54 kilograms) in the past 3 months
- currently participating in another weight loss program
- having had bariatric surgery in the past 2 years or plans on getting it in the near future
- planning on moving away from Montreal within the next year
- having another member of one's household enrolled in the program.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Enriched GLB
This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
|
Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
Autres noms:
|
Comparateur actif: Standard GLB
This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
|
This arm is the standard Group Lifestyle Balance program
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Percent body weight loss
Délai: 3 months after beginning of the intervention
|
The primary outcome will be percent body weight loss from baseline to 3 months after the beginning of the intervention.
Weight in kg.
|
3 months after beginning of the intervention
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Percent body weight loss
Délai: 12 months
|
Percent body weight loss 12 months after the beginning of the intervention.
Weight in kg.
|
12 months
|
Percent body weight loss
Délai: 24 months
|
Percent body weight loss 24 months after the beginning of the intervention.
Weight in kg.
|
24 months
|
Personal weight loss goal
Délai: 3 months
|
Reaching percent body weight loss goal (7% of body weight) from baseline to 3 months after the beginning of the intervention.
Weight in kg.
|
3 months
|
Personal weight loss goal
Délai: 12 months
|
Reaching percent body weight loss goal (7% of body weight) 12 months after the beginning of the intervention.
Weight in kg.
|
12 months
|
Personal weight loss goal
Délai: 24 months
|
Reaching percent body weight loss goal (7% of body weight) 24 months after the beginning of the intervention.
Weight in kg.
|
24 months
|
Personal exercise goal
Délai: 3 months
|
Reaching exercise goal (150 min/week) from baseline to 3 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
3 months
|
Personal exercise goal
Délai: 12 months
|
Reaching exercise goal (150 min/week) 12 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
12 months
|
Personal exercise goal
Délai: 24 months
|
Reaching exercise goal (150 min/week) 24 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
24 months
|
Waist circumference
Délai: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
Waist circumference
Délai: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
Waist circumference
Délai: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
Hemoglobin A1c levels
Délai: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
Hemoglobin A1c levels
Délai: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
Hemoglobin A1c levels
Délai: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
Blood pressure
Délai: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
Blood pressure
Délai: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
Blood pressure
Délai: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
Total cholesterol/HDL ratio
Délai: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
Total cholesterol/HDL ratio
Délai: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
Total cholesterol/HDL ratio
Délai: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
Physical activity duration
Délai: 3 months
|
Total minutes per week.
|
3 months
|
Physical activity duration
Délai: 12 months
|
Total minutes per week.
|
12 months
|
Physical activity duration
Délai: 24 months
|
Total minutes per week.
|
24 months
|
Number of steps taken per week
Délai: 3 months
|
Steps taken per week, recorded using a pedometer.
|
3 months
|
Number of steps taken per week
Délai: 12 months
|
Steps taken per week, recorded using a pedometer.
|
12 months
|
Number of steps taken per week
Délai: 24 months
|
Steps taken per week, recorded using a pedometer.
|
24 months
|
Exercise stress test (EST)
Délai: 3 months
|
3 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Self-Report Index of Habit Strength
Délai: 3 months
|
Self-monitoring and behaviors
|
3 months
|
Self-Report Index of Habit Strength
Délai: 12 months
|
Self-monitoring and behaviors
|
12 months
|
Self-Report Index of Habit Strength
Délai: 24 months
|
Self-monitoring and behaviors
|
24 months
|
Habit formation indices of weight tracking
Délai: 3 months
|
Frequency of weight tracking.
|
3 months
|
Habit formation indices of weight tracking
Délai: 12 months
|
Frequency of weight tracking.
|
12 months
|
Habit formation indices of weight tracking
Délai: 24 months
|
Frequency of weight tracking.
|
24 months
|
Habit formation indices of physical activity tracking
Délai: 3 months
|
Frequency of physical activity tracking.
|
3 months
|
Habit formation indices of physical activity tracking
Délai: 12 months
|
Frequency of physical activity tracking.
|
12 months
|
Habit formation indices of physical activity tracking
Délai: 24 months
|
Frequency of physical activity tracking.
|
24 months
|
Habit formation indices of fat grams and calorie tracking
Délai: 3 months
|
Frequency of food tracking.
|
3 months
|
Habit formation indices of fat grams and calorie tracking
Délai: 12 months
|
Frequency of food tracking.
|
12 months
|
Habit formation indices of fat grams and calorie tracking
Délai: 24 months
|
Frequency of food tracking.
|
24 months
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Directeur d'études: Ilka Lowensteyn, PhD, McGill University
- Directeur d'études: Lawrence Joseph, PhD, McGill University
- Directeur d'études: Aleksandra Luszczynska, PhD, University of Colorado, Denver
- Directeur d'études: Steven Grover, MD, McGill University
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Knauper B, Shireen H, Carriere K, Frayn M, Ivanova E, Xu Z, Lowensteyn I, Sadikaj G, Luszczynska A, Grover S; McGill CHIP Healthy Weight Program Investigators. The effects of if-then plans on weight loss: results of the 24-month follow-up of the McGill CHIP Healthy Weight Program randomized controlled trial. Trials. 2020 Jan 7;21(1):40. doi: 10.1186/s13063-019-4014-z.
- Knauper B, Carriere K, Frayn M, Ivanova E, Xu Z, Ames-Bull A, Islam F, Lowensteyn I, Sadikaj G, Luszczynska A, Grover S; McGill CHIP Healthy Weight Program Investigators. The Effects of If-Then Plans on Weight Loss: Results of the McGill CHIP Healthy Weight Program Randomized Controlled Trial. Obesity (Silver Spring). 2018 Aug;26(8):1285-1295. doi: 10.1002/oby.22226. Epub 2018 Jun 28.
- Knauper B, Ivanova E, Xu Z, Chamandy M, Lowensteyn I, Joseph L, Luszczynska A, Grover S. Increasing the effectiveness of the Diabetes Prevention Program through if-then plans: study protocol for the randomized controlled trial of the McGill CHIP Healthy Weight Program. BMC Public Health. 2014 May 18;14:470. doi: 10.1186/1471-2458-14-470.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 avril 2013
Achèvement primaire (Réel)
1 décembre 2017
Achèvement de l'étude (Réel)
1 décembre 2017
Dates d'inscription aux études
Première soumission
6 décembre 2013
Première soumission répondant aux critères de contrôle qualité
6 décembre 2013
Première publication (Estimation)
11 décembre 2013
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
21 mars 2018
Dernière mise à jour soumise répondant aux critères de contrôle qualité
20 mars 2018
Dernière vérification
1 mars 2018
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- MOP-123242
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Enriched GLB
-
GluBio Therapeutics Inc.RecrutementLeucémie myéloïde aiguë | Syndromes myélodysplasiquesÉtats-Unis
-
University of PittsburghUnited States Department of DefenseComplétéSyndrome métabolique | PrédiabèteÉtats-Unis
-
Hangzhou GluBio Pharmaceutical Co., Ltd.RecrutementLymphome non hodgkinienChine
-
Hangzhou GluBio Pharmaceutical Co., Ltd.Pas encore de recrutementLeucémie myéloïde aiguë | Syndromes myélodysplasiques | Polyglobulie Vera | Thrombocytémie essentielle | Myélofibrose | Malignité myéloïdeChine
-
Lovoria WilliamsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recrutement
-
Ohio State UniversityComplété
-
University of PittsburghComplétéQualité de vie | Obésité | Activité physique | Modification du régime | Facteur de risque cardiovasculaire | Limitation de la mobilité | Comportement alimentaire
-
University of PittsburghRobert C. Atkins FoundationComplété
-
Baylor Research InstituteActif, ne recrute pasHypertension | Comportement de réduction des risques | Afro-américains | Régime alimentaire restreint en glucidesÉtats-Unis
-
Baylor Research InstituteCenters for Disease Control and PreventionComplétéLimitation de la mobilité